Hepatocellular adenoma: An update

Vijay, Adarsh; Elaffandi, Ahmed; Khalaf, Hatem

doi:10.4254/wjh.v7.i25.2603

Cited by 27 publications

(20 citation statements)

References 48 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular adenomas (HCAs) is a very rare disease with malignant potential in Asian, but is highly prevalent in Europe [1]. The annual incidence of HCA is estimated to be 1/10 6 among all population and 3 to 4 per 100,000 women with long-term use of oral contraceptives [2,3].…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Transarterial embolization for hepatocellular adenomas: a literature review

Yuan¹,

Li²,

Ahir³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Since the utilization of transarterial embolization (TAE) for hepatocellular carcinoma, TAE is used to treat bleeding hepatocellular adenomas (HCAs) and occasionally, in symptomatic HCAs with large tumors. However, the role of TAE in an elective setting is uncertain. The present review aims to evaluate the benefits and harms of TAE in bleeding and non-bleeding HCAs, especially in an elective setting. A systematic review of studies published from January 2000 to December 2016 in the EMBASE, PubMed and Scopus databases was performed. Avoidance of resection and tumor reduction after TAE were the primary outcomes measure in both bleeding and non-bleeding HCAs. Twenty-one case series involving 1481 patients with HCAs were included in the analysis. Most of them were underwent hepatic resection. Only 148 (10%) patients (involving 189 lesions) received TAE, including 93 (62.8%) patients with bleeding HCAs and 55 (37.2%) patients with non-bleeding HCAs. Based on data of 107 tumors, the rates of Complete Response and Partial Response were 10.3% and 73.8%, respectively. Hepatic resection was avoided in 72 of 148 (48.6%) TAE treated patients. Intended elective TAE was performed in 45/148 (30.4%) patients; 95.6% of them did not require further hepatic resection. No mortality or adverse side effects were reported during the hospitalization period. Therefore, Either in an elective setting or in the setting of bleeding, TAE can be considered safe in the management of HCAs. In the elective setting, TAE can be regarded as a reasonable alternative management to hepatic resection. High-quality prospective study with long-term follow-up is warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Transarterial embolization for hepatocellular adenomas: a literature review

Yuan¹,

Li²,

Ahir³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…HCA is a rare monoclonal benign liver tumor, which originates in the epithelium and usually develops within a healthy liver (18). HCA is more prevalent in females than in males and the use of oral contraceptives and anabolic steroids are established risk factors for the disease (19). Recent research has focused on the etiology, clinical manifestations and diagnosis of HCA (19).…”

Section: Discussionmentioning

confidence: 99%

“…HCA is more prevalent in females than in males and the use of oral contraceptives and anabolic steroids are established risk factors for the disease (19). Recent research has focused on the etiology, clinical manifestations and diagnosis of HCA (19). However, its functionality as a liver-derived tumor is rarely characterized.…”

Section: Discussionmentioning

confidence: 99%

Human hepatocellular adenoma as a promising cell source for bioartificial liver systems

et al. 2019

View full text Add to dashboard Cite

“…Hepatic adenoma (HA) is a rare, benign tumor of epithelial origin (2% of all liver tumors [1]) that develops usually in healthy liver [2] and is known to occur mainly in young female patients, having been linked to the prolonged use of oral contraceptives [3]. In Europe and North America, it has an incidence of 3/100,000/ year [4].…”

Section: Introductionmentioning

confidence: 99%

Challenging Issues in Hepatic Adenoma

Boeți¹,

Tivadar²,

Lupescu³

et al. 2019

Liver Disease and Surgery [Working Title]

View full text Add to dashboard Cite

Hepatic adenoma is known as a benign lesion encountered mainly in female patients and classically linked to the administration of oral contraceptives. In the last decade, the risk factors for its occurrence have changed and so did the sex ratio. The histopathological classification of hepatic adenomas was found to be related with certain genetic mutations that determine the risk for malignancy. The diagnosis of hepatic tumor is correlated with clinical and imaging data in an effort not only to rule out other tumors but also to distinguish the subtype of adenoma, which is very important for the management of the patient. The ultimate diagnosis is established by pathologists by routine histopathological and specific immunohistochemical staining. There are two major issues that pathologists need to recognize: the presence of β-catenin gene mutation and/or malignant degeneration. The best imaging examination is considered to be MRI. However, along with MRI, ultrasound and computer tomography have proved themselves to be effective not only in evaluating the number, size, localization, and complications of hepatic adenomas, but also in identifying their subtype. A detailed presentation of characteristics of all groups of hepatic adenoma is provided. The means of management of hepatic adenomas are documented and decisional algorithm is explained, based on certain criteria.

show abstract

Hepatocellular adenoma: An update

Cited by 27 publications

References 48 publications

WITHDRAWN: Transarterial embolization for hepatocellular adenomas: a literature review

WITHDRAWN: Transarterial embolization for hepatocellular adenomas: a literature review

Human hepatocellular adenoma as a promising cell source for bioartificial liver systems

Challenging Issues in Hepatic Adenoma

Contact Info

Product

Resources

About